In the past few years there have been several developments in the field of head and neck oncology, including major advances in systemic therapy. We propose this Research Topic on "Advances in the systemic therapy and combined modality approaches for head and neck cancer" to provide a timely overview of emerging concepts in the systemic treatment of head and neck cancer and the evolving treatment paradigm in locally advanced disease. It will encompass reviews on combined modality approaches in locally advanced SCCHN as well as the current and upcoming role of targeted therapies and immunotherapy in SCCHN.
Suggested topics:
1. Combining radiation therapy and immunotherapy for SCCHN
2. Cisplatin eligibility issues and alternative regimens in locally advanced SCCHN
3. Cetuximab-containing combinations in recurrent or metastatic and locally advanced SCCHN
4. HPV positive oropharyngeal cancer: emerging combined modality approaches
5. Postoperative combined modality treatment in locally advanced SCCHN
6. Prognostic and predictive factors in recurrent or metastatic SCCHN
7. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers
8. Patient volumes and outcomes in head and neck cancer
9. Beyond EGFR targeting in SCCHN: angiogenesis, PI3K , and other molecular targets
10. Supportive care for patients with head and neck cancer: the role of the medical oncologist
In the past few years there have been several developments in the field of head and neck oncology, including major advances in systemic therapy. We propose this Research Topic on "Advances in the systemic therapy and combined modality approaches for head and neck cancer" to provide a timely overview of emerging concepts in the systemic treatment of head and neck cancer and the evolving treatment paradigm in locally advanced disease. It will encompass reviews on combined modality approaches in locally advanced SCCHN as well as the current and upcoming role of targeted therapies and immunotherapy in SCCHN.
Suggested topics:
1. Combining radiation therapy and immunotherapy for SCCHN
2. Cisplatin eligibility issues and alternative regimens in locally advanced SCCHN
3. Cetuximab-containing combinations in recurrent or metastatic and locally advanced SCCHN
4. HPV positive oropharyngeal cancer: emerging combined modality approaches
5. Postoperative combined modality treatment in locally advanced SCCHN
6. Prognostic and predictive factors in recurrent or metastatic SCCHN
7. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers
8. Patient volumes and outcomes in head and neck cancer
9. Beyond EGFR targeting in SCCHN: angiogenesis, PI3K , and other molecular targets
10. Supportive care for patients with head and neck cancer: the role of the medical oncologist
